Clinical trials
Colorectal Cancer Recurrent clinical trials
Below are recruiting colorectal cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 234 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05908643RecruitingPhase 1/Phase 2
First test of pTTL for advanced colorectal cancer
This trial tests pTTL, a personalized cancer treatment made from your tumor and immune cells, in people with advanced (stage IV) colorectal cancer. It’s designed to see whether pTTL is safe and potentially effective when standard treatments have been used or can’t be used.
Stockholm, Stockholm CountyAges 18 years+ - NCT05930496Recruiting
Exercise after colorectal cancer to change gut bacteria
This study tests whether a structured exercise program can improve the makeup of gut microbiota (gut bacteria) in people who have finished treatment for stage II–III colorectal cancer. It may help learn how exercise supports recovery, and it involves remote or in-person sessions with gut-focused tracking.
Seattle, WashingtonAges 18–70 - NCT05985109RecruitingPhase 2
KN 046 plus regorafenib for advanced colorectal cancer
This trial tests a combination of two drugs, KN 046 and regorafenib, in people with a type of advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
BeijingAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06207006Recruiting
Online program for fear of cancer returning
This trial tests an online program to help Chinese cancer survivors who have a moderate fear of their cancer returning. It is for people who recently finished treatment for early-stage colorectal or breast cancer.
Hong KongAges 18 years+ - NCT06207656RecruitingPhase 2
Targeted therapy for BRAF V600E mutated colorectal cancer
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
MadridAges 18 years+ - NCT06229340RecruitingPhase 2
Two drug combinations for advanced cancer with RAS mutations
This trial tests two different treatment combinations (leflunomide alone or with MEK inhibitor and hydroxychloroquine) in people with advanced cancer that has a RAS mutation and has not responded to at least two prior therapies.
Saint PetersburgAges 18–85 - NCT06307548RecruitingPhase 1/Phase 2
Image-guided surgery and light therapy for colorectal cancer
This trial tests a special dye that helps surgeons see tumors more clearly during surgery, followed by a light therapy to destroy any remaining cancer cells. It is for people with advanced or returning colorectal cancer who are already scheduled for surgery.
Buffalo, New YorkAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT06349590RecruitingPhase 1/Phase 2
Diet before colon cancer surgery to reduce recurrence
This trial tests whether a specific diet before colon cancer surgery can change the bacteria in your gut to help prevent the cancer from coming back or spreading. Patients who are eligible will follow the diet for a short time before their operation.
Chicago, IllinoisAges 18 years+ - NCT06371768Recruiting
Helping Young Cancer Survivors Manage Symptoms & Transition to Care
This study is designed to help adolescent and young adult cancer survivors manage symptoms and smoothly transition to post-treatment care. If you finished treatment for certain cancers within the past 1 to 5 years, you may be able to join.
Durham, North CarolinaAges 18–39 - NCT06405139RecruitingPhase 2
Chemo combo (nanoliposomal irinotecan, oxaliplatin, capecitabine) before surgery for locally advanced colorectal cancer
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
BeijingAges 18–70 - NCT06487377RecruitingPhase 1
IX001 TCR-T for advanced KRAS-mutated pancreatic and colorectal cancer
This trial tests a new treatment called IX001 TCR-T, which uses your own immune cells to target cancer cells with a specific KRAS mutation. It's for people with advanced pancreatic or colorectal cancer who have run out of standard options.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06520683RecruitingPhase 3
Immunotherapy after surgery for high-risk stage II colorectal cancer
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
Guangzhou, GuangdongAges 18–80 - NCT06524245Recruiting
Predicting Colorectal Cancer Recurrence with Portal Vein Blood
This study looks at blood from a special vein near your liver (portal vein) to find markers that might predict if colorectal cancer will come back. The goal is to create a better way to identify patients who may need closer monitoring after surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06543836RecruitingPhase 2
Targeted therapy plus immunotherapy for advanced colorectal cancer
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06566755RecruitingPhase 3
New drug combo for a common type of colorectal cancer
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
Shenyang, LiaoningAges 18–75 - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06314958Recruiting
Follow-up after colorectal cancer treatment
This study follows people who have finished treatment for stage II (high-risk) or stage III colorectal cancer and are now cancer-free. Researchers want to learn more about which factors might predict if the cancer will come back, so they can better personalize follow-up care.
Monrovia, CaliforniaAges 18 years+ - NCT07226115Recruiting
Predicting chemotherapy outcomes for colorectal cancer
This trial uses a special test on your tumor tissue to see if it can predict how well chemotherapy will work for you. If you have had chemotherapy for stage II or III colorectal cancer after surgery, your stored tumor sample may help develop a tool that could guide future treatment decisions.
Duarte, CaliforniaAges 18–80 - NCT06734156Recruiting
Gut microbiome study in colorectal cancer patients
This study looks at how bacteria and other microbes in your gut are linked to colorectal cancer risk and outcomes. By collecting stool samples from people newly diagnosed with colorectal cancer, researchers hope to find patterns that could improve understanding and future treatments.
Lisbon, Lisbon DistrictAges 40–74 - NCT06741293Recruiting
Improving colorectal cancer early screening with stool tests
This study looks for markers in stool (poop) to detect colorectal cancer early. If you are between 40 and 74, live in the Lisbon area, and don't have certain digestive or cancer conditions, you may help improve screening by providing a stool sample.
Lisbon, Lisbon DistrictAges 40–74 - NCT06769828Recruiting
Ga-68-FAPI-46 PET scan for colorectal cancer recurrence with rising CEA
This trial tests a new type of PET scan called Ga-68-FAPI-46 to help find if your colorectal cancer has returned when your CEA levels are rising. It might offer a more accurate way to detect recurrence early.
Taipei, BeitouAges 20–100 - NCT06776757RecruitingPhase 1/Phase 2
Sintilimab plus cetuximab and chemo for first-line advanced colorectal cancer
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
Shenzhen, GuangdongAges 18–75
Hear when a new Colorectal Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer recurrent?
- Yes. Clin2 currently lists 234 recruiting colorectal cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.